The US Food and Drug Administration has approved Tearson's new transducer featuring AxoTrack needle visualization technology, according to a statement released by the company.
The AxoTrack needle visualization technology has been developed by Soma Access Systems. Tearson said that it is the first company to offer Soma's AxoTrack technology for ultrasound systems and added that the innovative combination will provide unprecedented real-time needle tracking for a variety of ultrasound-guided procedures.
"Terason's award-winning ultrasound systems, coupled with AxoTrack revolutionary technology, combine to create another unique user experience for our customers. We are proud to partner with Soma to pioneer the use of this technology and change the way many doctors approach needle guidance procedures", Tearson CEO John Bridge said.